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ABSTRACT
Introduction: Randomised controlled trials (RCTs)
should have well-defined primary and secondary
outcomes to answer questions generated by the main
hypotheses. However, for the chronic, inflammatory
skin disease hidradenitis suppurativa (HS), the reported
outcome measures are numerous and diverse. A recent
systematic review found a total of 30 outcome measure
instruments in 12 RCTs. This use of a broad range of
outcome measures can increase difficulties in
interpretation and comparison of results and may
potentially obstruct appropriate evidence synthesis by
causing reporting bias. One strategy for dealing with
these problems is to develop a core outcome set
(COS). A COS is a list of outcomes that are meant as
mandatory and should be measured and reported in all
clinical trials. The aim of this study is to develop a COS
for the management of HS.
Method and analysis: An international steering
group of researchers, clinicians and a patient research
partner will guide the COS development. 6 stakeholder
groups are involved: patients, dermatologists,
surgeons, nurses, industry representatives and drug
regulatory authorities. A 1:1 ratio of patients:healthcare
professionals is aimed for. The initial list of candidate
items will be obtained by combining three data sets:
(1) a systematic review of the literature, (2) US and
Danish qualitative interview studies involving patients
with HS and (3) an online healthcare professional
(HCP) item generation survey. To reach consensus on
the COS, 4 anonymous online Delphi rounds are then
planned together with 2 face-to-face consensus
meetings (1 in Europe and 1 in the USA) to ensure
global representation.
Ethics and dissemination: The study will be
performed according to the Helsinki declaration. All
results from the study, including inconclusive or
negative results, will be published in peer-reviewed
indexed journals. The study will involve different
stakeholder groups to ensure that the developed COS
will be suitable and well accepted.
INTRODUCTION
Evidence-based and consensus-endorsed
outcome measures are necessary to ensure
that study results are comparable and that
patients, in consequence, receive the most
effective and suitable treatments. Measuring
disease activity is therefore crucial to devel-
opment of new therapies.
Hidradenitis suppurativa (HS) is a chronic
inﬂammatory skin disease characterised by
repeated outbreaks of painful inﬂamed
nodules or boils in the apocrine gland-
bearing regions (axillae, genital area, groin,
breasts and perianal region). Nodules may
progress to sinus tracts and scarring.1 The
estimated prevalence is 1–4% worldwide, and
HS is three times more common in women
than in men.2–4 HS is associated with signiﬁ-
cant disability and handicap due to pain and
subsequent loss of mobility.5 The active con-
dition is associated with malodorous dis-
charge that stains clothing, and HS is
therefore accompanied by embarrassment,
disabling social stigma, low self-worth and a
strong negative impact on interpersonal
relationships, education and work.6–9
Strengths and limitations of this study
▪ The number of trials is increasing in hidradenitis
suppurativa (HS), and a well-defined core
outcome set (COS) will reduce the risk of
outcome reporting bias and heterogeneity across
studies.
▪ The protocol is designed to systematically iden-
tify what to measure in HS trials (an HS-specific
COS).
▪ The protocol ensures input from major HS stake-
holders including patients.
▪ The protocol and the study involves different
stakeholder groups from different countries and
cultures.
▪ Limitations include that the qualitative studies
will be performed on Western (Danish and US)
patients only. Asian and Eastern European
patients will be invited to take part in Delphi
surveys to compensate for this.
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Interventions for HS are diverse and include topical
treatment, systemic antibiotics, anti-inﬂammatory
therapy, biologics and surgical therapy including laser
surgery.10
Clinical measurements for assessing the severity of HS
have generally been based on the Hurley staging
system.1 Other used clinical measures include the
‘Modiﬁed Sartorius Score’ (MSS),11 the ‘HS Physician’s
Global Assessment’ (HS-PGA)12 and, most recently, the
‘Hidradenitis Suppurativa Clinical Response’ (HiSCR).13
A recent Cochrane review identiﬁed a substantial hetero-
geneity of outcome measures in previous randomised
controlled trials (RCTs) on interventions for HS.14
CURRENT SELECTION OF OUTCOMES FOR USE IN
CLINICAL TRIALS ON INTERVENTIONS FOR HS
Clinical trials should have well-deﬁned primary and sec-
ondary outcomes to answer questions generated by the
main hypotheses. For HS, however, reported outcome
measures are numerous with a total of 30 outcome
measure instruments in the 12 RCTs included in a
recent systematic review.15 No consensus on core out-
comes for HS exists. Researchers therefore use various
instruments, which may or may not be representative.
This can cause the following problems:
▸ Heterogeneity in instruments limiting meta-analysis.16
▸ Outcome reporting bias involving selective reporting
of more favourable outcomes. Empirical evidence of
this phenomenon has been highlighted in the
literature.17
One strategy to deal with these issues is development
of a core outcome set (COS).18–20 A COS is a list of out-
comes that should be measured and reported in all clin-
ical trials. Robust development of a COS ensures that
researchers report on outcomes that are relevant to all
major stakeholders.20 Cochrane editors have further-
more stated that the availability of COSs would improve
reliability of reviews.21
AIMS AND OBJECTIVES
Aim
The aim of this study is to develop a COS suitable for
trials on the management of HS. The COS is intended
to suit all types of interventions for HS, regardless of
setting or mode of administration.
Objectives
Study objectives are:
1. To identify a list of items and domains previously
used in studies on the management of HS by a sys-
tematic review of the literature.
2. To develop a list of items relevant to HS disease sever-
ity generated by patients.
3. To develop a list of items relevant to HS disease sever-
ity generated by HS experts.
4. To combine the results of (1)—(3) into a uniﬁed list
of candidate HS disease severity items for HS trials
and use these to formulate potential core domains.
5. To achieve consensus on core domains for trials by
in-person consensus meetings and online Delphi
surveys including patient and HCP representatives at
all stages.
Scope of the COS
Our intention is that the HS COS should apply to efﬁcacy
measures of all interventions in clinical trials on patients
with HS globally. In accordance with the COMET deﬁn-
ition, this does not necessarily mean that primary out-
comes of clinical trials should always be chosen from this
COS or that outcome measurers should be restricted to
domains belonging to the COS. It is intended that
domains of this COS should be considered mandatory
for inclusion in all clinical trials on HS so that, in most
trials, the primary outcome instrument would usually be
one of those contained in the COS. If the primary
outcome for a particular trial is not within the COS, then
an explanation of the author’s decision should be pro-
vided in the protocol and subsequent trial report.20
METHODS AND ANALYSIS
Initiatives like Core Outcome Measures in Effectiveness
Trials (COMET)20 and Outcome Measures in
Rheumatology (OMERACT)22 provide methodological
guidance that will be followed. The methodology
involves a stepwise approach for the development of a
COS. The ﬁrst step is to identify which domains one
should measure and report in all clinical controlled
trials of a speciﬁc condition (what to measure: the
domain set, COS).16 The second step is identifying the
instruments that should be used to assess these domains
(how to measure: the core outcome measurement set,
COMS).18 20 The second step includes the possible need
for development and validation of new instruments for
domains that do not have valid outcome measure
instruments.
This protocol focuses on the initial step, describing
the method we will use to reach consensus on the core
domain set. A summary of the study method can be
found in ﬁgure 1. The OMERACT initiative has recently
outlined deﬁnitions of key concepts and terms that we
will adhere to throughout the protocol.18 A guideline on
the usage of the Delphi technique for determining
which outcomes to measure in clinical trials and the
enclosed checklist will be followed.23 The checklist from
the COMET initiative will also be adhered to.20
HISTORIC
The HIdradenitis SuppuraTiva cORe outcomes set
International Collaboration (HISTORIC) is an inter-
national initiative arising from collaboration between the
International Dermatology Outcome Measures organisa-
tion (IDEOM), the Cochrane Skin Group—Core
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Outcome Set Initiative (CSG-COUSIN) and Zealand
University Hospital, Roskilde. HISTORIC goals are to:
▸ Develop global COSs for HS trials including the most
relevant core domain set and adequate, that is, valid,
reliable and feasible, instruments to measure the core
domains using an iterative process of evidence synthe-
sis and multistakeholder consensus.
▸ Implement the COS on a global level.
An international steering group consisting of research-
ers, clinicians and a patient research partner under the
HISTORIC initiative has been formed to guide the
development of the COS. The steering group consists of
nine members; a patient research partner who is a
board member of the HS Patients’ Association in
Denmark, two dermatologists with expertise in HS
research and clinical work; four dermatologists with a
special interest in outcome measures in dermatology
and in HS; a biostatistician from OMERACTexperienced
in COS development and an MD Ph.D. student.
Stakeholder involvement
We will involve researchers, HCPs, patients, government
agencies and industry representatives.20 The involvement
of multiple stakeholders for the development of a COS
is strongly recommended by COS methodologists.18 20 23
For the development of the HS-COS, the steering group
decided on involving six groups of stakeholders:
1. Patients (invites: 30 European, 30 North American,
10–20 Asian/South American/Australian).
2. Dermatologist HS experts (invites: 20 European,
20 North American, 10 Asian/South American/
Australian).
3. Surgeons HS experts (invites: 4 European, 4 North
American).
4. Nurses HS specialist (invites: 4 European, 4 North
American).
5. Industry representatives (invites: 2).
6. Drug regulatory authorities (invites: 2).
For practical reasons—including ease of interpretabil-
ity—the steering group decided to analyse patients as
one stakeholder group and stakeholder group 2–6
together as another combined stakeholder group of
healthcare professionals (HCPs). A 1:1 ratio of patients:
HCPs will be aimed for with the target of ∼50–70 partici-
pants in each group.
Eligibility criteria
Identification and sampling
Patients
All board members from the Danish, English, German,
Belgian, Austrian, French, Dutch and US HS patients’
associations will be invited. If the number of patients
from patient associations are not sufﬁcient, the steering
group will identify additional patients. From Austria,
Asia, Australia and Africa, three patients from each area
will be identiﬁed following contact with a local derma-
tologist with a special interest in HS.
Inclusion criteria:
▸ Conﬁrmed diagnosis of HS.
▸ Agrees to participate in all Delphi rounds needed for
this COS.
Exclusion criteria:
▸ Inadequate English skills.
▸ No access to internet.
HCPs
The steering group will identify the HCPs from the
limited but growing community of HCPs working with
patients with HS. Purposive sampling will be conducted
according to the following criteria:
1. Commitment: Agrees to participate in all Delphi
rounds needed for this COS
2. Knowledge: A clinical background with at least 5 years
of experience with HS and at least six patients with
HS treated per year
Figure 1 Study summary. See
the text for details. HCP,
healthcare professional.
Thorlacius L, et al. BMJ Open 2017;7:e014733. doi:10.1136/bmjopen-2016-014733 3
Open Access
 o
n
 26 April 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-014733 on 20 February 2017. Downloaded from 
3. Involvement: Publications on HS or participation in
scientiﬁc meetings on HS (Dermatologist HS experts
only)
4. Representability: Geography
5. Representability: Occupation (dermatologist, nurse, etc)
6. Representability: Institution (clinic, university, regional
hospital, non-governmental organization, etc)
7. Representability: Sex
Information sources
Identification of initial list of candidate items and potential
core domains
The initial list of candidate items will be obtained in a
three-step manner.
Systematic review of the literature
A recent systematic Cochrane review on interventions
for HS and another systematic review on outcome
measure instruments have reviewed existing instruments
and mapped them according to domains.14 15
Qualitative studies
A representative group of patients with HS will be identi-
ﬁed from the outpatient clinic at the Department of
Dermatology, Zealand University Hospital, Roskilde,
Denmark.
The patients will be interviewed individually and in
focus groups. The number of patients sampled will be
determined by an assessment of when saturation is
achieved, and no new knowledge is obtained from subse-
quent interviews. On the basis of previous experience, a
sample size of 20–30 patients should be sufﬁcient to
reach saturation. Purposive sampling of a wide diversity
of age groups, sex, treatment types and disease severities
will be employed.
Patients will be identiﬁed primarily among
those undergoing treatment at the Department of
Dermatology at Roskilde Hospital, as well as through
the patient association in Denmark. Eligibility is based
on the diagnosis of HS (conforming to the modiﬁed
Dessau criteria and provided by a specialist in derma-
tology)10 and willingness to participate. All three
Hurley stages will be represented among the intervie-
wees. Analysis of the interviews aims at identifying
central topics of general relevance using thematic
analysis.
The interviews will be tape recorded and transcribed
verbatim and initially examined for units of meaning,
coded as items and grouped into categories whenever a
topic is identiﬁed as having HS-speciﬁc importance. The
individual interviews will be supplemented by focus
group interviews, improving the item-generating process.
The focus group participants may be a mix of former
participants and new participants, which also gives room
for new items.
The focus group interviews will be semistructured
based on the analysis of the single interviews. The focus
group interviews will also be tape recorded, but only
partly transcribed, omitting ‘obligatory small talk’. The
analysis will be an iterative process moving back and
forth between transcripts and analysis of single inter-
views and focus group interviews. On the basis of this
analysis, a list of items will be developed, covering a
whole range of individual perspectives on HS. This
qualitative method provides a depth of insight into the
complexity of meaning and reasoning in relation to HS.
Focus group interviews will continue until the point of
saturation when no further new items are identiﬁed.
Qualitative interviews do not require ethical approval in
Denmark.
A similar qualitative study will be performed in North
America. Semistructured interviews will be performed in
person by one interviewer. Transcripts will be reviewed
line-by-line after each interview and words, phrases and
passages related to symptoms and effects on life will be
coded using NVivo V.10 (QSR International, Burlington,
MA). These codes will be used to inform subsequent
interviews. Preliminary codes will be reviewed, and then
the ﬁnal analytical codes will be applied and grouped
into themes. The interviews will proceed until thematic
saturation. This project has been approved by the institu-
tional review board of the Penn State College of
Medicine.
The two lists of potential items generated from the
Danish and US qualitative studies will be combined into
one patient-generated item list.
Identification of items of importance to HCPs
To identify outcomes of importance to HCPs, an item
generation Delphi round 0 will be conducted among
the HCPs stakeholder group (HS experts; dermatolo-
gists, surgeons, nurses, industry representatives and regu-
lators). Participants will be invited by email (see online
supplementary material A). Two reference articles on
COS development will be attached to the invitation.18 20
Delphi round 0 will be presented as an online survey
using the SurveyMonkey software. Initially, the HCPs will
be provided with one page of background information
on the rationale for the development of the COS (see
online supplementary material B). They will then be
asked to list all items that they consider important or
relevant to HS, with items being related to any aspect of
the disease, or treatment of the disease (see online
supplementary material C). The open questions will
ensure that no one will impose their views on the partici-
pants and thus introduce bias into the study. This
implies that participants will suggest potential items
without being prompted or guided by facilitators, the
steering group or by reviews of the literature. This is in
line with the recommendations outlined in Delphi
guidelines.23
The steering group will review the list of items sug-
gested by the HCPs. A preliminary list of potential items
will be produced by combining the results from the sys-
tematic reviews, from the qualitative studies and from
the HCPs’ item generation survey.
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Consensus process
Methods to reach consensus on the core domain set
To make sure that the views of participants are obtained
by a method that gives equal inﬂuence to all participants
and to ensure that no individual participant will be
overtly inﬂuenced by the opinions of any others, an
anonymous Delphi approach will be applied. The
Delphi method facilitates consensus with geographically
scattered participants through consecutive Delphi
rounds. Participants are asked to rate the importance of
the listed items. Participants will also be provided with
an option to add additional items that they think are
missing together with a scoring for each item added. A
minimum of three Delphi rounds is planned. Two
face-to-face consensus meetings are planned in Europe
and the USA between e-Delphi rounds two and three to
ensure the global reach of the COS. Representatives
from the USA will be present at the European meeting
and vice versa. The steering group decided not to invite
pharmaceutical industry representatives to the
face-to-face meetings to ensure that the process is driven
by patients and HCPs.
The Delphi survey will be presented online using
DelphiManager software. Panel members will be asked
to participate in all rounds of the survey (see online
supplementary materials A and D). A study information
sheet will be attached to the patient invitation (see
online supplementary material E).
Once participants have registered for the survey,
names and email addresses will be stored in a separate
database in the system and will be used for providing the
participant with a unique identiﬁer code. This code will
allow identiﬁcation of participants completing all rounds
of the Delphi survey.
People with minority opinions are more likely to drop
out of a consensus process, so attrition as rounds pro-
gress can lead to overestimation of consensus in the
ﬁnal results. To prevent attrition bias, participants will
receive an explanation of the importance of completing
the whole Delphi process with a paragraph adapted
from the guideline on the usage of the Delphi
Technique23 (Box 1). The number of participants
invited to participate will be documented together with
the number of recruited participants. The number of
participants completing subsequent rounds will also be
documented and attrition assessed.
Participation will be fully anonymised, and participants
will not know the speciﬁc answers that any other individ-
ual gave.
The steering group will design the questionnaires and
will be responsible for sending out invitations and
reminders to panel members, analysing the responses
and drawing up feedback reports. Invitations will be sent
by email. Each round will be online for 7–10 days, and
reminder emails will be sent.
Questionnaires used in the Delphi survey will be pilot-
tested by at least two members of the steering group,
including the patient representative, and at least two
selected other panel members.
Items/domain scoring
Participants will be asked to score each item/domain
listed using the Grading of Recommendations,
Assessment, Development and Evaluations scale from
1 to 9. In the Delphi exercise, scores 1–3 will be labelled
‘not important’, 4–6 labelled ‘ important but not critical’
and 7–9 labelled ‘ critical’.24
Definition of consensus
The classiﬁcations outlined in table 1 will be used to
decide whether consensus is reached or not.
Criteria for ‘rule in’ and for ‘rule out’ are symmet-
rical. To reach consensus that an item/domain should
be in the COS requires agreement by the majority
regarding the critical importance of the item/domain,
with only a small minority considering it to be not
important at all. By comparing the proportions voting
critical among HCPs and patients, when both propor-
tions are above the 70% threshold from the Delphi exer-
cise, this will indicate that these domains should be
considered part of the COS. To reach consensus that an
item/domain should not be in the COS, on the other
Box 1 Commitment to completing the entire Delphi
process
Thank you for agreeing to participate in the process aimed at
identifying the most important features in clinical trials about HS.
It is very important that you complete the survey in each round.
You may feel that you answer the same questions several times,
or the results of previous rounds may show that other partici-
pants do not agree with you. Anyway, it is very important that
everyone participates in all surveys. If some participants drop out
of the study before it is complete, the total results may become
useless.
Table 1 Definition of consensus
Consensus
classification Description Definition
Consensus in Consensus that
item/domain
should be included
in the core domain
set
70% or more
participants
scoring 7–9 AND
<15% participants
scoring 1–3
Consensus out Consensus that
item/domain
should not be
included in the
core domain set
70% or more
participants
scoring 1–3 AND
<15% of
participants
scoring 7–9
No consensus Uncertainty about
importance of
item/domain
Anything else
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hand, requires agreement by the majority regarding the
lack of importance of the item/domain, with only a
small minority considering it to be critically important.
While the choice of thresholds is somewhat arbitrary,
prospective speciﬁcation of the deﬁnition of consensus
should reduce the chance of consensus being deﬁned
post hoc in such a way as to bias the results towards the
beliefs of the research team.
Delphi round 1
The invitation for the ﬁrst round will be sent to all parti-
cipants by email (see online supplementary material F).
The ‘plain language summary’ from the COMET initia-
tive,25 deﬁning outcome measures and explaining the
purpose of COS development, will be attached to the
invitation. The survey will be presented in an online
format. First, the participants will be asked to provide
background demographic information including age,
geographical region, conﬁrmed diagnosis of HS (for
patients), years living with HS (for patients), years of
experience with HS and number of HS contacts per year
(HCPs).
On the next page, participants will be provided with
some background information explaining how the can-
didate items have been identiﬁed and will then be asked
to rate each of the items listed, based on their import-
ance in being measured as an outcome in all clinical
trials for HS (see online supplementary material G). It is
emphasized that the items are all relevant to the overall
care of people with HS, but for the purposes of the
survey it is essential that participants decide whether
each item is important/essential to be measured in all
clinical trials on HS. The order of the candidate items
will be randomised. The panel members will be encour-
aged to provide arguments for their choices and to
suggest modiﬁcations of deﬁnitions or wording of the
items. Panel members will also be asked to suggest items
not represented in the list together with a rating for
each item added.
Items suggested by the panel members will be
reviewed by the steering group to ensure that they repre-
sent new items. If they do, the new items will be added
to the list for the next round. For each item, the
number of participants who have scored the item and
the distribution of scores will be summarised by the
stakeholder group (patients and HCPs). All items will be
carried forward to round 2.
Delphi round 2
Only participants who have taken part in round 1 and
have provided scores will be invited to participate in
round 2. Survey participants will be shown the number
of participants who have scored each item and the distri-
bution of scores (as a percentage of the total) as graphs
by the stakeholder group (patients and HCPs).
Participants will be asked to consider responses from the
other panel members and to re-score the items.
Response options will be the same as in the ﬁrst round.
Consensus meetings
First meeting
After the two ﬁrst online surveys, a face-to-face consensus
meeting will be held in Europe with representatives
from all stakeholders including US stakeholders. An
equal ratio of HCP:patients will be aimed for.
Stakeholders who are not able to participate in person
will be invited to join the meeting via Skype (Microsoft,
USA).
The meeting format will be a mixture of small group
work followed by plenary sessions, based on nominal
group theory. The meeting will begin with a broad intro-
duction to the HISTORIC collaboration and a summary
of the reasoning for COS development. The study
method and results from the ﬁrst two rounds of the
Delphi survey will be presented. Topics for the small
group sessions will be item ranking, items to exclude,
grouping of items into domains and ranking of
domains. For each task, two small groups will work inde-
pendently and in parallel, supervised in each case by a
non-voting facilitator. Results from each group will be
presented to all participants in the subsequent plenary
session. The aim is to get all items either designated to
an appropriate domain or excluded by in-person
consensus.
Consensus meeting 2
Since the ﬁrst consensus meeting will take place in
Europe, making it difﬁcult for North Americans to par-
ticipate, a second consensus meeting located in the USA
is planned.
Group work sessions will be held to conﬁrm and
adjust results from the ﬁrst consensus meeting.
Questions that will be raised are:
1. Should any deleted item be retained?
2. Do all the items ﬁt within their designated domain?
3. Should any combined items form their own domain
(s)?
4. Is the naming for each domain appropriate?
Confirmation of results from the consensus meeting by the
larger Delphi group
A feedback report of the results of the two consensus
meetings will be emailed to all Delphi participants.
Participants will be asked the same four questions that
were addressed at the second consensus meeting. The
steering group will consider all comments and sugges-
tions for changes and adjust if there is consensus in the
steering group.
Delphi round 3
In round 3 of the e-Delphi, the items that have not
been excluded at the consensus meetings will be shown
under their designated domain, following the work
from the in-person meetings. Items that have been
excluded at the consensus meeting will be shown separ-
ately under no speciﬁc domain. Participants will be
shown the distribution of scores in the second round
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for each item as graphs by the stakeholder group.
Participants will also be shown the proportion voting
‘critical’ in round 2 by the stakeholder group and com-
bined for the two groups. They will be asked to con-
sider the responses from the other members and to
re-score each item.
Results of the two stakeholder group responses will be
compared with each other and reported as the percent-
age of agreement, giving an equal weight to the two
stakeholder groups. Each item will be classiﬁed as ‘con-
sensus in’, ‘consensus out’ or ‘no consensus’ according
to the classiﬁcation in table 1. Items classiﬁed as ‘con-
sensus in’ will be used to provide a detailed deﬁnition of
each domain. The name of the domains will be adjusted
if needed. If an item that was excluded at the consensus
meeting reaches ‘consensus in’, the item will be
included in one of the existing domains or will be
carried forward to round 4 as a separate domain.
Delphi round 4
In round 4, participants will vote on the domains only.
Domains will be deﬁned by their included items.
Each domain will be classiﬁed as ‘consensus in’, ‘con-
sensus out’ or ‘no consensus’ according to the classiﬁca-
tions in table 1. Domains classiﬁed as ‘consensus in’ will
be the ﬁnal core domains.
Statistical considerations
Sample size
Until now, there is no existing standard method for
sample size calculation in Delphi surveys. Therefore, a
pragmatic approach will be taken, ensuring broad demo-
graphic and geographic representation from patients
with HS and HCPs. Sample sizes of 40–60 patients and
40–60 HCPs are expected to provide sufﬁcient represen-
tation. Efforts will be taken to maximise the response
rate across stakeholder groups.
DISCUSSION
The absence of evidence-based, consensus-driven and
widely accepted outcome measures is likely to impede
access of patients with HS to the most effective and
appropriate treatments available. Consensus regarding
outcome measures further beneﬁts researchers and
HCPs by providing critical benchmarks for making treat-
ment recommendations and evaluating patient progress.
Payers will also receive information needed to determine
the efﬁcacy of various treatments, information that is key
to shaping payment policies. The absence of clear
outcome measures could result in payers providing
minimal to no coverage for various therapies, curtailing
patient access to care.
The number of RCTs of HS therapy is limited, but the
interest in the disease and planned number of trials is
signiﬁcant. Therefore, a COS process is particularly
timely for HS and identifying a COS for HS should sig-
niﬁcantly impact future developments within the ﬁeld.10
At the time of writing, there is no published COS for
HS. The development of COS for the management of
HS aims to improve the interpretation and comparison
of future studies on HS and to reduce the risk of
outcome reporting bias and heterogeneity across studies.
The study will involve different stakeholder groups to
ensure that the developed COS will be suitable and well
accepted. The initial steps described in this protocol
have been conducted. Consensus meeting 2 and Delphi
round 3 and 4 await.
Dissemination
The study will be performed according to the Helsinki
declaration. All results from the study, including incon-
clusive or negative results, will be published in peer-
reviewed journals.
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